Payment overview · 2025
General Payments
$162.38
9 reported records · 5 companies
Healthcare provider profile · identity verified
Mark Sells, NP-C
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner · DANVILLE, VA · NPI 1497089387
Verified facts
What the public records show
CMS Open Payments records show Mark Sells, NP-C received $162.38 in general payments during 2025 across 9 reported records.
Novo Nordisk Inc accounted for 42.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Rybelsus.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VIBERZI as an associated drug or biological on 11354 records involving 5020 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Viberzi by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $69.13 | 42.6% | 3 | 2025 |
| Supernus Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $38.65 | 23.8% | 2 | 2025 |
| Advanced Oxygen Therapy Inc. | Unresolved — no canonical attribution shown | $22.66 | 13.9% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $17.69 | 10.9% | 1 | 2025 |
| Smith+Nephew, Inc. | Unresolved — no canonical attribution shown | $14.25 | 8.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $162.38 | 9 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $40.66 | 2 | 2025 |
Source payment records
|
|||||
| Qelbree Normalized: qelbree |
Drug | Supernus Pharmaceuticals, Inc. | $38.65 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $28.47 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $28.47 | 1 | 2025 |
Source payment records
|
|||||
| Topical Oxygen Chamber for extremities Normalized: topical oxygen chamber for extremities |
Device | Advanced Oxygen Therapy Inc. | $22.66 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $17.69 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $17.69 | 1 | 2025 |
Source payment records
|
|||||
| COLLAGENASE SANTYL Normalized: collagenase santyl |
Drug | Smith+Nephew, Inc. | $14.25 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
49 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VIBERZI open payments reported associated product |
CMS Open Payments — General Payments 11354 supporting records · 5020 recipient NPIs · example record 1201352948 |
Viberzi · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 436 | 78 |
| Atorvastatin Calcium | Atorvastatin Calcium | 412 | 66 |
| Amlodipine Besylate | Amlodipine Besylate | 401 | 71 |
| Omeprazole | Omeprazole | 223 | 40 |
| Gabapentin | Gabapentin | 217 | 35 |
| Lisinopril | Lisinopril | 217 | 43 |
| Metformin Hcl | Metformin Hcl | 205 | 29 |
| Furosemide | Furosemide | 202 | 39 |
| Eliquis | Apixaban | 193 | 36 |
| Escitalopram Oxalate | Escitalopram Oxalate | 188 | 31 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 161 | 45 |
| Losartan Potassium | Losartan Potassium | 156 | 28 |
| Simvastatin | Simvastatin | 134 | 21 |
| Tamsulosin Hcl | Tamsulosin Hcl | 126 | 20 |
| Pantoprazole Sodium | Pantoprazole Sodium | 120 | 31 |
| Hydralazine Hcl | Hydralazine Hcl | 119 | 18 |
| Duloxetine Hcl | Duloxetine Hcl | 110 | 23 |
| Metoprolol Tartrate | Metoprolol Tartrate | 108 | 26 |
| Nystatin | Nystatin | 103 | 28 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 102 | 21 |
| Montelukast Sodium | Montelukast Sodium | 102 | 18 |
| Jardiance | Empagliflozin | 100 | 24 |
| Potassium Chloride | Potassium Chloride | 93 | 22 |
| Metoprolol Succinate | Metoprolol Succinate | 92 | 20 |
| Famotidine | Famotidine | 79 | 18 |
| Mirtazapine | Mirtazapine | 79 | 20 |
| Carvedilol | Carvedilol | 78 | 19 |
| Fluticasone Propionate | Fluticasone Propionate | 75 | 22 |
| Trazodone Hcl | Trazodone Hcl | 74 | 16 |
| Pravastatin Sodium | Pravastatin Sodium | 73 | 11 |
| Donepezil Hcl | Donepezil Hcl | 70 | 12 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 67 | 18 |
| Alprazolam | Alprazolam | 67 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 64 | suppressed |
| Torsemide | Torsemide | 63 | 11 |
| Hydrochlorothiazide | Hydrochlorothiazide | 60 | 14 |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 59 | suppressed |
| Januvia | Sitagliptin Phosphate | 59 | suppressed |
| Prednisone | Prednisone | 58 | 31 |
| Xarelto | Rivaroxaban | 58 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 55 | 13 |
| Azelastine Hcl | Azelastine Hcl | 54 | suppressed |
| Allopurinol | Allopurinol | 53 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 52 | suppressed |
| Risperidone | Risperidone | 52 | suppressed |
| Linzess | Linaclotide | 49 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 44 | 12 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 43 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 42 | 11 |
| Fenofibrate | Fenofibrate | 42 | suppressed |
| Lorazepam | Lorazepam | 42 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 40 | 13 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 39 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 39 | 15 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 38 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 36 | 12 |
| Vascepa | Icosapent Ethyl | 36 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 34 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 31 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 31 | suppressed |
| Ezetimibe | Ezetimibe | 30 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 29 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 29 | suppressed |
| Meloxicam | Meloxicam | 28 | suppressed |
| Clonazepam | Clonazepam | 27 | suppressed |
| Invokana | Canagliflozin | 27 | suppressed |
| Latanoprost | Latanoprost | 27 | 11 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 26 | suppressed |
| Glimepiride | Glimepiride | 26 | suppressed |
| Fluconazole | Fluconazole | 25 | suppressed |
| Memantine Hcl | Memantine Hcl | 25 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 25 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Celecoxib | Celecoxib | 23 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 23 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 23 | suppressed |
| Aripiprazole | Aripiprazole | 22 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 22 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 22 | suppressed |
| Hydrocortisone | Hydrocortisone | 22 | suppressed |
| Ondansetron Odt | Ondansetron | 22 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 22 | suppressed |
| Cephalexin | Cephalexin | 21 | 12 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 21 | 17 |
| Midodrine Hcl | Midodrine Hcl | 21 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 21 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 20 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 20 | suppressed |
| Lansoprazole | Lansoprazole | 20 | suppressed |
| Pregabalin | Pregabalin | 20 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 20 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 19 | suppressed |
| Diazepam | Diazepam | 19 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 19 | suppressed |
| Novolog Flexpen | Insulin Aspart | 19 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 19 | suppressed |
| Telmisartan | Telmisartan | 19 | suppressed |
| Baclofen | Baclofen | 18 | suppressed |
| Myrbetriq | Mirabegron | 18 | suppressed |
| Nystop | Nystatin | 18 | suppressed |
| Rexulti | Brexpiprazole | 18 | suppressed |
| Valsartan | Valsartan | 18 | suppressed |
| Glipizide Er | Glipizide | 17 | suppressed |
| Spironolactone | Spironolactone | 17 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 17 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 16 | suppressed |
| Lamotrigine | Lamotrigine | 16 | suppressed |
| Levetiracetam | Levetiracetam | 16 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 16 | suppressed |
| Tradjenta | Linagliptin | 16 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 15 | suppressed |
| Levofloxacin | Levofloxacin | 15 | 14 |
| Lovastatin | Lovastatin | 15 | suppressed |
| Methocarbamol | Methocarbamol | 15 | suppressed |
| Rybelsus | Semaglutide | 15 | suppressed |
| Sucralfate | Sucralfate | 15 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 15 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 15 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 14 | suppressed |
| Bupropion Xl | Bupropion Hcl | 14 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 14 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 14 | suppressed |
| Olanzapine | Olanzapine | 14 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 14 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 13 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 13 | suppressed |
| Felodipine Er | Felodipine | 13 | suppressed |
| Loperamide | Loperamide Hcl | 13 | suppressed |
| Mupirocin | Mupirocin | 13 | suppressed |
| Nateglinide | Nateglinide | 13 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 13 | suppressed |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 13 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 13 | suppressed |
| Viberzi | Eluxadoline | 13 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 12 | suppressed |
| Chlorthalidone | Chlorthalidone | 12 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 12 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 12 | suppressed |
| Fesoterodine Fumarate Er | Fesoterodine Fumarate | 12 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Lidocaine | Lidocaine | 12 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 12 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 12 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 12 | suppressed |
| Roflumilast | Roflumilast | 12 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 12 | suppressed |
| Topiramate | Topiramate | 12 | suppressed |
| Valproic Acid | Valproic Acid | 12 | suppressed |
| Zonisamide | Zonisamide | 12 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 11 | suppressed |
| Desmopressin Acetate | Desmopressin Acetate | 11 | suppressed |
| Levetiracetam Er | Levetiracetam | 11 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 11 | suppressed |
| Phenobarbital | Phenobarbital | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $162.38 · 9 records | Novo Nordisk Inc | COLLAGENASE SANTYL, Ozempic, QULIPTA, Qelbree, Rybelsus, Topical Oxygen Chamber for extremities, UBRELVY, Wegovy | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Rybelsus play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error